A Phase I, Dose Escalation Study of BNC101 (Anti-LGR5 Humanized Monoclonal Antibody) in Patients With Metastatic Colorectal Cancer.

Trial Profile

A Phase I, Dose Escalation Study of BNC101 (Anti-LGR5 Humanized Monoclonal Antibody) in Patients With Metastatic Colorectal Cancer.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs BNC 101 (Primary)
  • Indications Colon cancer; Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Bionomics
  • Most Recent Events

    • 21 Nov 2017 Planned primary completion date changed from 1 Apr 2019 to 1 Jan 2018.
    • 21 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 20 Apr 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top